First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers — Robert M. Wenham (2011) | RDL Network
First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers
R.M. Wenham, Shahneen Sandhu, George Wilding, Linda Sun, Carlo Toniatti, Mark Stroh, Catherine L. Carpenter, Johann S. de Bono, Richard D. Baird, William R. Schelman
William R. Schelman, Shahneen Sandhu, Víctor Moreno, G. Wilding, Long Sun, Carlo Toniatti, Mark Stroh, N. Kreischer, Celia L. Carpenter, L. Rhoda Molife, S. B. Kaye, Johann S. de Bono, R.M. Wenham
Shahneen Sandhu, G. Wilding, William R. Schelman, Aurelius Omlin, N. Kreischer, Catherine L. Carpenter, Raffaele Iannone, Stuart Kaye, Johann S. de Bono, R.M. Wenham
Shahneen Sandhu, William R. Schelman, George Wilding, Víctor Moreno, Richard D. Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Förster, Aurelius Omlin, N. Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John W. Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L. Carpenter, Robert Iannone, Stan B. Kaye, Johann S. de Bono, Robert M. Wenham
Discussion(0)
No comments yet. Be the first to comment.